About Us

Founder of Jubilant Bhartia Group, valued at around US $5 Billion and 42,000 employees globally, has a leadership position in diverse sectors like Pharmaceuticals, Contract Research and Development Services, Proprietary Novel Drugs, Life Science Ingredients, Agri Products, Performance Polymers, Food Service (QSR), Food, Auto, Consulting in Aerospace and Oilfield Services.

Member of World Economic Forum’s International Business Council; Community of Chairpersons; Global Health and Healthcare Governors Community; Family Business Community. He was the Co-Chair of the Davos Annual Meeting of the World Economic Forum in 2015.

Dr. Alland is currently Chief Medical Officer of PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, and a Member of the Board of Directors, Jubilant Therapeutics.

Leila, a pediatric hematologist-oncologist and accomplished physician-scientist, has been working in the biopharmaceutical industry since 2001 to bring novel therapies to patients. Previously, Dr. Alland served as Chief Medical Officer at Affimed, and prior to that she held the same position at Tarveda Therapeutics. Dr. Alland also held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she worked on a broad range of oncology products from early to late-stage development and contributed to multiple successful drug approvals.

Earlier in her career, Leila served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine, where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer and blood disorders. Dr. Alland is on the Board of Directors of Abeona Therapeutics, Inc. and Cytovia Therapeutics, Inc. Leila is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research and serves as a scientific reviewer for the Cancer Prevention and Research Institute of Texas.

Leila obtained her medical degree from New York University School of Medicine, and her B.A. in Biology from the University of Pennsylvania. She completed her residency in Pediatrics at The Children’s Hospital of Philadelphia, and her fellowship in Pediatric Hematology/Oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center.

Mr. Patel is a management consultant and corporate director. He currently serves as senior strategic advisor at global law firm Norton Rose Fulbright Canada LLP, managing director at Fairfax Consulting Services, and strategic advisor to the President of Huron University at Western. He concurrently serves on the board of directors of Canadian Tire Corporation where he also chairs the audit committee, as well as board Chairman at Canadian Tire Jumpstart Charities.

Prior to his current roles, Mr. Patel held several senior government positions over a distinguished career in Canada’s public service. Most recently, he served as Canada’s High Commissioner for the Republic of India, with concurrent accreditation as Canada’s Ambassador to Nepal and Ambassador to the Kingdom of Bhutan until 2021. He also previously served as Assistant Deputy Minister and Chief Financial Officer for Canada’s Department of Foreign Affairs, Trade and Development and as Canada’s Consul General in Shanghai. He brings a wealth of experience in strategic planning, finance, human resources, risk management, information technology, procurement, and international relations, and has served on the boards of several public, private, crown corporation, and not-for-profit organizations.

Mr. Patel holds a joint MBA from New York University’s Stern School of Business, London School of Economics and Political Science, and HEC (Paris) School of Management.